Candel Therapeutics (CADL) announced the appointment of Carl H. June, M.D., to Candel’s Research Advisory Board. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine, in the Perelman School of Medicine at the University of Pennsylvania. He is also the Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Extends Lease Agreement in Needham
- Candel Therapeutics Advances with Promising Cancer Therapies
- Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment
- Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential
- Candel Therapeutics: Promising Pipeline Developments and Strategic Advancements Support Buy Rating